INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 186 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $0 | – | 50 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 50 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 50 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | – | 50 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 50 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 50 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $2,000 | 0.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $2,000 | -33.3% | 50 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $3,000 | -40.0% | 50 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $5,000 | +66.7% | 50 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $3,000 | 0.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $3,000 | -40.0% | 50 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $5,000 | +25.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $4,000 | -33.3% | 50 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $6,000 | +50.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $4,000 | +33.3% | 50 | 0.0% | 0.00% | +100.0% |
| Q1 2018 | $3,000 | +50.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $2,000 | 0.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,000 | -66.7% | 50 | 0.0% | 0.00% | -66.7% |
| Q2 2017 | $6,000 | +20.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $5,000 | 0.0% | 50 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $5,000 | -37.5% | 50 | 0.0% | 0.00% | -40.0% |
| Q3 2016 | $8,000 | +14.3% | 50 | 0.0% | 0.01% | +25.0% |
| Q2 2016 | $7,000 | +16.7% | 50 | 0.0% | 0.00% | +33.3% |
| Q1 2016 | $6,000 | -14.3% | 50 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $7,000 | -12.5% | 50 | 0.0% | 0.00% | -25.0% |
| Q3 2015 | $8,000 | -33.3% | 50 | 0.0% | 0.00% | -20.0% |
| Q2 2015 | $12,000 | -14.3% | 50 | 0.0% | 0.01% | -16.7% |
| Q1 2015 | $14,000 | -30.0% | 50 | -60.0% | 0.01% | -33.3% |
| Q4 2014 | $20,000 | -33.3% | 125 | 0.0% | 0.01% | -52.6% |
| Q3 2014 | $30,000 | -57.7% | 125 | -58.3% | 0.02% | -76.5% |
| Q2 2014 | $71,000 | – | 300 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |